Legend Biotech Corp ADR LEGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Legend Biotech Reports Third Quarter 2026 Results and Recent Highlights
Gabelli Releases Agenda for 8th Annual Healthcare Symposium
Legend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026
Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results
Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy
Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma
Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion
Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
Trading Information
- Previous Close Price
- $15.99
- Day Range
- $15.75–16.50
- 52-Week Range
- $15.75–37.50
- Bid/Ask
- $16.36 / $16.46
- Shares Outstanding
- 193.97M
- Market Cap
- $3.12B
- Volume/Avg
- 3M / 2M
Key Statistics
- Price/Earnings (Normalized)
- 27.78
- Price/Sales
- 2.27
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 3,300
Valuation
Metric | LEGN |
|---|---|
Price/Earnings (Normalized) | 27.78 |
Price/Book Value | 2.57 |
Price/Sales | 2.27 |
Price/Cash Flow | 17.58 |
Price/Earnings
LEGN
Financial Strength
Metric | LEGN |
|---|---|
Quick Ratio | 3.70 |
Current Ratio | 3.95 |
Interest Coverage | 1.14 |
Quick Ratio
LEGN
Profitability
Metric | LEGN |
|---|---|
Return on Assets (Normalized) | 6.54% |
Return on Equity (Normalized) | 10.86% |
Return on Invested Capital (Normalized) | 7.17% |
Return on Assets
LEGN
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|%%!<!< | LOCK|xWjf | $135B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|??&xbZ | LOCK|Qd<R | $99B | |||
| Moderna Inc MRNA | LOCK|B@x$M! | LOCK|&kB | $84B | |||
| argenx SE ADR ARGX | LOCK|%HFr^n | LOCK|>#k | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|#BXx^% | LOCK|lYC | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|RJtLxrjp | LOCK|SYX%T | $31B | |||
| Incyte Corp INCY | LOCK|Y!d^<@ | LOCK|sj | $24B | |||
| BioNTech SE ADR BNTX | LOCK|q#?VqPq | LOCK|Wh | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|&z@nRy | LOCK|vCvL | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|$WXd!C | LOCK|l$C | $15B |